Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

Luto expands to Switzerland with new office

The Basel office places the company at the heart of Europe’s life sciences sector

- PMLiVE

Setting your sights – the marketing objectives that guide everything that follows

Strong brands need clear objectives – the four steps to avoiding wombat marketing

- PMLiVE

J&J receives three CHMP recommendations for immunology and oncology indications

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

- PMLiVE

The full potential of patient journeys in pharma

Unlocking three actions to take now

- PMLiVE

Navigating market access: Launch strategies and health economic modelling for medical devices – a live panel discussion

Discover how health economics can support successful Medical Device launch, proposition development, and market access. Join us live at 1:30pm (GMT) on Wednesday 19th March for an insightful journey into...

Petauri Evidence

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

EU flag

Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

There is currently only one treatment authorised for the ultra-rare genetic blistering disease

- PMLiVE

Key clinical trial trends – EU vs US perspectives

Highlighting the distinct priorities and hurdles faced by sponsors, CROs and sites around the world

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links